Sanofi en­lists Ada­gene and its 'mask­ing' tech to de­vel­op new I/O drugs, in a deal po­ten­tial­ly worth $2.5B

Sanofi is putting to­geth­er a new, multi­bil­lion dol­lar deal aim­ing to leap in­to the next gen­er­a­tion of im­muno-on­col­o­gy.

The French phar­ma signed a col­lab­o­ra­tion with Ada­gene on Tues­day to ad­vance two pre­clin­i­cal I/O can­di­dates, and an op­tion to de­vel­op two more. Sanofi is pony­ing up $17.5 mil­lion up­front and promis­ing up to $2.5 bil­lion in po­ten­tial mile­stones.

The deal is slight­ly un­ortho­dox rel­a­tive to how these deals usu­al­ly shake out, as both of the ini­tial pro­grams come from Sanofi’s de­vel­op­ment pipeline — not Ada­gene’s. But the com­pa­nies are aim­ing to link those com­pounds to what Ada­gene calls a “mask­ing” tech­nol­o­gy that can bet­ter se­lec­tive­ly tar­get tu­mor mi­croen­vi­ron­ments than cur­rent ap­proach­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER